Fast track and the pediatric emergency department: resource utilization and patients outcomes

L C Hampers1, S Cha, D J Gutglass

  • 1Division of Pediatric Emergency Medicine, Children's Memorial Hospital, Northwestern University Medical School, Chicago, IL, USA. hampers.lou@tchden.org

Insights

Pediatric patients in a fast track (FT) unit had fewer tests and shorter stays than those in the main emergency department (ED). Outcomes and satisfaction were similar, demonstrating FT efficiency for low-acuity cases.

Area of Science:

  • Pediatric Emergency Medicine
  • Healthcare Management
  • Clinical Operations

Background:

  • Emergency departments (EDs) often face overcrowding due to high volumes of low-acuity patients.
  • Fast track (FT) systems are designed to manage these patients more efficiently.
  • Evaluating the comparative effectiveness of FT versus main ED care is crucial for optimizing resource allocation.

Purpose of the Study:

  • To compare patient evaluation, management, and outcomes between an on-site fast track (FT) unit and the main emergency department (ED).
  • To assess the impact of FT care on resource utilization, length of stay, and patient satisfaction for non-urgent pediatric cases.

Main Methods:

  • Prospective assessment of pediatric patients (2 months to 10 years) triaged as non-urgent over a three-month period.
  • Patients in FT received evening/weekend care; others seen in the main ED.
  • Telephone interviews conducted seven days post-visit to assess outcomes.

Main Results:

  • FT patients had significantly lower mean test charges ($27 vs $52) and fewer tests performed (24% vs 41%) compared to main ED patients.
  • Average length of stay was 28 minutes shorter in the FT.
  • No significant differences were observed in patient improvement (90% vs 88%), unscheduled follow-up care (18% vs 15%), or overall family satisfaction (94% vs 94%).

Conclusions:

  • Fast track (FT) care for low-acuity pediatric patients resulted in reduced testing and shorter lengths of stay compared to the main emergency department (ED).
  • These efficiencies were achieved without compromising patient outcomes or satisfaction.
  • FT models offer a viable strategy for improving ED throughput and resource management for non-urgent pediatric conditions.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).